BiomEdit, Inc. is an animal health microbial biotechnology company headquartered in Greenfield, Indiana, that leverages synthetic biology and the microbiome.
Subscribe to see BiomEdit’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
BiomEdit is a biotechnology company headquartered in Fishers, United States. Its most recent funding round, Series B, raised $18.4M in July 2025. Xcout tracks 8 named people at BiomEdit, including Aaron Schacht (CEO).
As of 16 November 2026. Source: Xcout Intel.
2 more named people on record for BiomEdit, with roles, board committees and tenure — see the full roster →
Every round on record:
| Date | Round | Amount | Investors |
|---|---|---|---|
| Series B | $18.4M | 5 named | |
| SEC Form D filing | $16M | — |
Who invested in each round, lead investors, valuations and the co-investor graph — open the full funding history →
A few of BiomEdit's closest competitors — see the full list of competitors and alternatives →
Hoofprint Biome, Inc. is at the forefront of the symbiotic agriculture movement, focusing on microbiome engineering to enhance livestock production and address human, animal, and planetary health.
MicrobiomX, Inc. is a technology company based in Seattle, Washington, that creates microbiome intervention tools for veterinary and health practices.
MBF Therapeutics, Inc. is an immunotherapeutics company utilizing its proprietary T-Max DNA vaccine technology to develop next-generation treatments for animal and human health.
Biomolecular Life Holdings, Inc. develops and commercializes precision nutrition products, luxury-grade nutritional supplements, and wellness technologies. The company serves both human consumers and the companion animal wellness market with science-backed formulations focused on longevity and preventive health.
Volta Greentech develops scientific feed additives for ruminant animals, such as cows and sheep, to suppress methane-producing microbes and reduce agricultural greenhouse gas emissions. The company serves farmers and food production companies by providing solutions that lower climate footprints while preserving feed energy for the animals.
PetVivo Holdings, Inc. operates as a biomedical technology firm, specializing in the invention, commercialization, and licensing of advanced medical devices and biomaterials intended to treat a variety of ailments and diseases affecting animals. Its flagship product is Spryng, an intra-articular injection administered by veterinarians to effectively alleviate lameness and joint conditions, such as osteoarthritis, in canines and equines. The company's development pipeline further includes seventeen therapeutic devices poised for both veterinary and human clinical applications. Founded in 2009, PetVivo Holdings, Inc. maintains its corporate headquarters in Minneapolis, Minnesota.
Funding rounds, acquisitions, new executives, launches and expansions, each with a two-line summary and a link to the source. One short email a day, only when there is news.
Free: up to 5 companies, daily. Subscribers also follow whole sectors and saved filters (M&A in Israel, AI funding…), get instant alerts, in-app notifications and signed webhooks, and open the full profile behind every name. Subscribe →
Something wrong or missing about BiomEdit? Suggest a correction · Work at BiomEdit? Claim this profile
Post the link and the card appears automatically — each network fetches the image itself.